Cytotherapy Journal Cover


Aims and Scope

Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. In addition to Short Reports and Full-Length Articles, the journal also accepts Editorials on emerging trends and potential controversies in the field, and Review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.

Cytotherapy considers manuscripts exploring the following topics:

  • Development and/or characterization of novel gene therapies and cell and/or EV-based therapeutics
  • Design of novel therapeutic approaches employing cell/EV/gene products.
  • Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
  • Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.
  • Role of stem/stromal cells and/or EVs in disease pathophysiology.
  • Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.
  • Important advances in cell/EV/gene-based product manufacturing and validation
  • Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.


Cytotherapy does not publish manuscripts on the following topics:

  • Case studies unless they are of unusual significance to the field.
  • Basic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiology
  • Studies describing signaling pathways implicated in cancer

Mission Statement

To be the premier cell and gene therapy translation journal.

Top Cited Articles

Powered by Scopus, most cited articles published since 2012:

1. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)

Journal: Volume 15, Issue 6, June 2013
Authors: Bourin, P.; Bunnell, B.A.; Casteilla, L.; Dominici, M.; Katz, A.J.; March, K.L.; Redl, H.; Rubin, J.P.; Yoshimura, K.; Gimble, J.M.

2. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

Journal: Volume 15, Issue 1, January 2013
Author: Galipeau, J.

3. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal

Journal: Volume 15, Issue 9, September 2013
Authors: MSC Committee of the International Society for Cellular Therapy (ISCT); Krampera, M.; Galipeau, J.; Shi, Y.; Tarte, K.; Sensebe, L.

4. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components

Journal: Volume 14, Issue 5, May 2012
Authors: Fekete, N.; Gadelorge, M.; Fürst, D.; Maurer, C.; Dausend, J.; Fleury-Cappellesso, S; Mailnder, V.; Lotfi, R.; Ignatius, A.; Sensebe, L.; Bourin, P. ; Schrezenmeier, H.; Rojewski, M.T. 

5. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

Journal: Volume 14, Issue 2, February 2012 
Authors: Francois, M.; Copland, I.B.; Yuan, S.; Romieu-Mourez, R.; Waller, E.K.; Galipeau, J.

6. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: A long-term safety study

Journal: Volume 14, Issue 1, January 2012
Author: Mazzini, L.; Kareschi, K.; Ferrero, I.; Miglioretti, M.; Stecco, A.; Servo, S.; Carriero, A.; Monaco, F.; Fagioli, F. 

7. Risk of tumorigenicity in mesenchymal stromal cell-based therapies - Bridging scientific observations and regulatory viewpoints

Journal: Volume 15, Issue 7, July 2013
Authors: Barkholt, L.; Flory, E.; Jekerle, V.; Lucas-Samuel, S.; Ahnert, P.; Bisset, L.; Buscher, D.; Fibbe, W.; Foussat, A.; Kwa, M.; Lantz, O.; Maciulaitis, R.; Palomaki, T.; Schneider, C.K.; Sensebe, L.; Tachdjian, G.; Tarte, K.; Tosca, L.; Salmikangas, P.

8. Phase I trial: The use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia

Journal: Volume 16, Issue 2, February 2014
Authors: Bura, A., Planat-Benard, V.; Bourin, P.; Silvestre, J.S.; Gross, F.; Grolleau, J.L.; Saint-Lebese, B.; Peyrafitte, J.A.; Fleury, S.; Gadelorge, M.; Taurand, M.; Dupuis-Coronas, S.; Leobon, B.; Casteilla, L.

9. Mesenchymal stromal cells and fibroblasts: A case of mistaken identity?

Journal: Volume 14, Issue 5, May 2012
Author: Hematti, P.

10. Is CD34 truly a negative marker for mesenchymal stromal cells?

Journal: Volume 14, Issue 10, November 2012
Authors: Lin, C.S.; Ning, H.; Lin, G.; Lue, T.F.

Journal Leadership


Edwin M. Horwitz, MD, PhD

Emory University School of Medicine
United States

Managing Editor

Kenneth W. Witwer, PhD

Johns Hopkins University
United States

Commissioning Editor

Patrick J. Hanley, PhD

Children's National Hospital
United States


Associate Editors

Shin Kawamata, MD, PhD
Sai-Kiang Lim, PhD 
A*STAR Institute of Molecular and Cell Biology Singapore
Susan Prockop, MD
Boston Children's Hospital
United States
Anna Pasetto, PhD
Karolinska Institutet
Sowmya Viswanathan, PhD
University Health Network
Qasim A. Rafiq, MEng, PhD
University College London
United Kingdom

Assistant Editor

Rachel A. Burga, PhD
Obsidian Therapeutics
United States

Cytotherapy logo

5-Year Impact Factor



Join us on Cytotherapy's LinkedIn and Elsevier's Hematology accounts on Twitter and Facebook.

Access Journal

For questions and issues about accessing Cytotherapy, contact Sam Baker:

Ande Nichols
Publisher, Cytotherapy

Cytotherapy logo

David Allan, MD, FRCPC
Ottawa Hospital Research Institute

Alice Bertaina, MD, PhD
Stanford School of Medicine
United States

Moanaro  Biswas, PhD
Indiana University School of Medicine
United States
Jaap Jan Boelens, MD, PhD
Memorial Sloan Kettering Center
United States
Mitchell  Cairo, MD
New York Medical College
United States
Rachele Ciccocioppo, MD
A.O.U.I. Policlinico G.B. Rossi & University of Verona
Charles Cox Jr., MD
McGovern Medical School
United States
Natividad Cuende, MD, MPH, PhD
Andalusian Transplant Coordination
Wanxing Cui, MD, PhD
Georgetown University Hospital
United States
Ekaterina Doubrovina, MD, PhD
Memorial Sloan-Kettering Cancer Center
United States
Nisha Durand, PhD
Mayo Clinic
United States
Miguel Forte, MD, PhD
AdBio Partners Inc
Jacques Galipeau MD,  FRCP©
University of Wisconsin-Madison
United States
Damian Garcia-Olmo, MD, PhD
Universidad Autónoma de Madrid
Bernd Giebel, PhD
University of Duisburg-Essen
Michael Gustafson, PhD
Mayo Clinic Arizona
United States
Steven M. Jay, PhD
University of Maryland
United States
Manoj Lalu, MD, PhD, FRCPC
The Ottawa Hospital
Bruce Levine, PhD
University of Pennsylvania School of Medicine
United States
Rebecca Lim, PhD
Prescient Therapeutics
Mark W. Lowdell, PhD, FRCPath, FRSB
University College London & Royal Free Hospital
United kingdom
Premal Lulla, MBBS
Baylor College of Medicine
United States
Martin Maiers, MS
United States
Nadim Mahmud, MD, PhD
University of Illinois College of Medicine
United States
Robert W. Mays, PhD
Athersys, Inc.
United States
Richard T. Maziarz, MD
Oregon Health & Science University
United States
David H. McKenna, MD
University of Minnesota Medical School
United States
Rosalia Mendez-Otero, MD, PhD
Universidade Federal do Rio de Janeiro
Bechara Mfarrej, PhD
Johnson and Johnson Innovative Medicine
Adriana Migliorini, PhD
University Health Network
Jeffrey J. Molldrem, MD
University of Texas 
United States
Sumimasa Nagai,  MD, PhD
Kyoto University Hospital
Robert  Nordon,  MBBS, BMedSc, PhD
University of New South Wales
Steve Oh, PhD
Cellvec, Smart MCs., Intellective Capital
Giuseppe Orlando, MD, PhD
Wake Forest Baptist Health 
United States
Luis Ortiz, MD
University of Pittsburgh
United States
Maryam A. Pasdar, B.S.
Children's National Hospital
United States
Nikita Patel, MSci, PhD
INmune Bio
United Kingdom
Royal Prince Alfred Hospital
Sharon Sagnella, PhD
Royal Prince Alfred Hospital
Fermin Sanchez-Guijo, MD, PhD
IBSAL-Hospital Universitario de Salamenca
Khalid Shah, MS, PhD
Harvard Medical School
United States
Akshay Sharma, MBBS
St. Jude's Children's Research Hospital
United States
Yufang Shi, PhD, MAE
The First Affiliated Hospital of Soochow University
Elizabeth J. Shpall, MD
University of Texas
                   MD Anderson Cancer Center
United States
Sandeep Soni, MD
CRISPR Therapeutics
United States
David Steffin, MD
Texas Children's Hospital
United States
Duncan Stewart, MD, FRCPC
Ottawa Hospital Research Institute
Paul Szabolcs, MD
UPMC Children's Hospital of Pittsburgh
United States
Satoshi Takahashi, MD, PhD
University of Tokyo, Institute of Medical Science 
Shuji Terai, MD, PhD, FAASLD
Niigata University
Torsten Tonn, MD
Medical Faculty Carl Gustav Carus, Technische Universität Dresden
Piotr Trzonkowski, MD, PhD
Medical University of Gdansk
Frits Van Rhee, MD, PhD, MRCP, FRCPath, FACP
University of Arkansas
United States
Beatriz Vega Blanco, PhD
Johnson and Johnson
Joaquim Vives, PhD
Banc de Sang i Teixits
Dominic Wall, PhD
Cell Therapies PTY Ltd
Hongjun Wang, PhD
Medical University of South Carolina
United States
Daniel J. Weiss, MD, PhD
University of Vermont
United States
Elani Wiest, PhD
Mayo Clinic 
United States
Joseph C. Wu, MD, PhD
Stanford University
United States

About the Journal

The journal's scope includes research in:

  • Stem cell processing and transplantation
  • Cell-based therapies of malignant and non-malignant blood diseases
  • CancerStem cell plasticity
  • Autoimmune diseases
  • Immunotherapy
  • Congenital disorders
  • Novel molecular therapies
  • Gene therapy
  • Microvesicle biology and therapeutic application

Readership and Target Group: Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists, and immunologists and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.

Keywords: Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.

Submit a Manuscript

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt, whether the manuscript is accepted, requires revision, or is rejected. All manuscripts will be published within 5 months from the date of acceptance.

Submit Now